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(71.2%) followed by cost of hospital stay (21.8%) and diag-
nostic costs (7%). Costs of hospital care for patients with ven-
tricular arrhythmias were signiﬁcantly higher as compared to
patients with heart failure (€5890.82 and €1959.35, respec-
tively). CONCLUSIONS: This study demonstrates that ARVC is
associated with high hospitalization costs in Poland, mainly due
to large costs of antiarrhythmic procedures.
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OBJECTIVES: To investigate different scenarios of warfarin
treatment for patients with non-valvular atrial ﬁbrillation who
are eligible to receive anticoagulation for stroke prevention. Sce-
narios include different proportions of eligible patients being
treated, as well as the level of anticoagulation obtained (i.e.
within and outside the recommended INR range). METHODS:
A decision-analytical model was constructed from a third party
payer perspective for the US. The model runs for ﬁve years in
yearly cycles. Strokes (fatal, major, minor and no deﬁcit) and
bleeding events (fatal, intracranial, major and minor) were
modeled. Probabilities and costs associated with events were
taken from published sources. Four scenarios were compared:
1). 100% of eligible patients warfarin treated and all within the
therapeutic range; 2). 100% of eligible patients’ warfarin treated
whereof 67% within and 33% outside the therapeutic range
(randomized controlled trial-like); 3). 100% of eligible patients
warfarin treated whereof 50% within/outside the therapeutic
range (routine practice INR levels); and 4). 55% warfarin treated
(of whom 50% within/outside recommended INR range), 5% no
treatment, and 40% aspirin (routine practice for warfarin treat-
ment rates and INR levels). RESULTS: At 5 years, total costs per
patient (discounted at 3%) and the total number of strokes per
1000 patients (discounted at 3%) were for strategy 1: $8607 and
25, for strategy 2: $12,518 and 46, for strategy 3: $14,582 and
58, and for strategy 4: $15,480 and 129, respectively. CON-
CLUSIONS: In a real world setting, evidence demonstrates that
patient’s eligible for anticoagulation may not be treated, and
those treated with warfarin may not be in the therapeutic range
for anticoagulation. This will lead to marked differences between
the observed efﬁcacy and effectiveness as demonstrated for the
number of strokes and costs in this model. This will need to be
addressed in any cost-effectiveness analysis using warfarin as
comparator.
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OBJECTIVES: Describe prevalence and characteristics of
patients with chronic nonvalvular atrial ﬁbrillation (NVAF) and
≥1 risk factor (RF) for thromboembolism in France in 2004, and
document reasons for vitamin K antagonists (VKA) underuse 
in those patients for whom anticoagulation is indicated.
METHODS: Cross sectional study. All patients with arrhythmia
or AF presenting to cardiologists (n = 43) from the THALES
observatory during a 3-month period were evaluated via ques-
tionnaire. Statistical comparisons were by chi2 and ANOVA
analyses. Data were extrapolated using the THALES database to
give representative national values. RESULTS: 409 patients met
the inclusion criteria, i.e., conﬁrmed NVAF and ≥1 thromboem-
bolic RF (mean age 76 years; mean number of thromboembolic
RF 2.11; 58.7% male). Of these, 37.2% had 1 RF, 28.9% had
2 RF and 34.0% had ≥3 RF. VKA was prescribed to 65.5% of
patients. VKA treatment was associated with a higher mean
number of RF (2.28) than aspirin (2.20) or no treatment (1.61).
Among VKA-treated patients, 18.6% were judged difﬁcult to
stabilise/not stabilised by the physician. Main reasons for not
prescribing VKA were insufﬁcient risk: beneﬁt (37.6%), patient’s
refusal due to VKA restrictions (23.4%) and patient’s inherent
haemorrhagic risk (19.1%). According to anticoagulation exclu-
sion criteria (severe hepatic insufﬁciency, recent stroke, and
patient’s inherent haemorrhagic risk) most patients not treated
with VKA (77.3%) would have been eligible for anticoagulation.
Extrapolation of these ﬁndings to the French population equated
to 426,731 (95% CI 420,099–433,363) patients with chronic
NVAF. Of these, 147,124 (34.5%) would not be treated with
VKA, even though 113,719 would have been eligible for anti-
coagulation. CONCLUSIONS: These data suggest that one 
third of French patients with chronic NVAF and ≥1 throm-
boembolic RF presenting to cardiologists are currently not
treated with VKA. Main drivers for this non-prescription are
more related to risk and constraints of VKA treatment than
formal contraindications.
PCV11
ANTICOAGULATION IN PATIENTS WITH NON-VALVULAR
ATRIAL FIBRILLATION: AN EVALUATION OF STABILITY AND
EARLY FACTORS THAT PREDICT LONGER-TERM STABILITY
ON WARFARIN IN A LARGE UK POPULATION
Currie CJ1, McEwan P2, Emmas C3, Peters JR4
1Cardiff University, Cardiff, UK; 2Cardiff University, Cardiff, Wales, UK;
3AstraZeneca-UK, Luton, Bedfordshire, UK; 4University Hospital of
Wales, Cardiff, UK
OBJECTIVES: To determine the proportion of patients with
non-valvular atrial ﬁbrillation (NVAF) treated with warfarin that
achieved INR stability. To then evaluate the associations between
stability and outcome, and factors that predict stability.
METHODS: A retrospective record linkage study in 1513
patients with NVAF treated with warfarin for a minimum of six
months. The setting was a large UK population (ª450,000
people). The main outcome measures were stability deﬁned as
six consecutive months within the target INR range (2.0–3.0),
thromboembolic and bleeding event rates, and mortality. Sec-
ondary outcome measures included the predictive value of base-
line characteristics and other treatment variables. RESULTS:
Stability was achieved in 52% of the study group. Standardised
mean survival was signiﬁcantly higher in the group who achieved
stability (D = 16.9 months, p < 0.001) with a hazard ratio of 4.36
(p < 0.001). The stable group had a lower rate of both throm-
boembolic events (0.8% vs. 2.3% per patient year) and major
bleeds (0.4% vs. 1.2% per patient year). Failure to achieve 
stability was associated with age (odds ratio 1.01 (95% CI
1.001–1.021)) and morbidity at baseline (OR 1.015; 95% CI
1.007–1.022). Greater variability in INR was also associated
with a failure to achieve stability (OR 1.518; 95% CI
1.427–1.615). Receiver operator characteristic (ROC) analysis
using data from the ﬁrst three month of treatment demonstrated
good discrimination of stability using age and morbidity at base-
line and percent time in range and frequency of visits during ﬁrst
three months treatment (AUC 0.780; SE 0.012; 95% CI
0.757–0.803). CONCLUSIONS: Many patients never achieved
A92 Abstracts
a consecutive 6-month period of stability and were at increased
risk of thromboembolic events and bleeding. Age, morbidity at
baseline and variability of INR control in the ﬁrst three-months
predicted instability using warfarin.
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OBJECTIVES: Atrial ﬁbrillation (AF) remains a major health
problem, affecting 2.2 million adults in the US with an estimated
cost burden of $3 billion annually. Treatment approaches vary
signiﬁcantly and can include both interventional and pharmaco-
logic options. The purpose of this research was to characterize
the clinical and economic impact associated with AF.
METHODS: Patients with continuous health beneﬁt eligibility
and a “new” diagnosis of AF (ICD-9-CM 427.3¥) were identi-
ﬁed from a large, geographically diverse administrative claims
database in the US (N = 43 million) between 1 January 2000 and
31 December 2001 with a variable follow-up period of ≥6
months. Warfarin-treated (WT) (N = 6,846) and untreated (UT)
(N = 40,849) cohorts were evaluated based on initial therapy
associated with the AF diagnosis. Study outcomes included
patient demography, treatment patterns and direct medical costs.
RESULTS: The AF cohorts were comprised of 58.5% males with
a mean age of 57.9 ± 15.8yrs; mean duration of follow-up was
~20 months. WT was initially received by 14% of this AF cohort
with only 37% receiving warfarin sometime during follow-up.
The WT cohort spent approximately 34% of their study follow-
up exposed to warfarin (average number of days on therapy =
206.5; average study duration = 608.7 days). Annualized AF-
related costs were $10,560 ± 290 (WT) versus $10,131 ± 143
(UT). CONCLUSIONS: Signiﬁcant proportions of AF patients
do not receive pharmacotherapy. Furthermore, pharmacotherapy
appeared to be sub-optimal among those who received it. Better
management of AF pharmacotherapy or uses of newer therapies
that provide appropriate anticoagulation are necessary to reduce
the burden associated with this costly disease.
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OBJECTIVE: Atrial Tachyarrhythmias (ATs) currently repre-
sents a major economic burden for society. Italian data on epi-
demiology and hospital costs of (ATs) are lacking. METHODS:
Prospective systematic evaluation of all consecutively Emergency
Room (ER) admitted patients with a diagnosis of AT in the
Alessandria, Novara, Novi Ligure and Tortona Hospitals from
November 2004 to January 2005. A group of clinicians and
economists developed an ad-hoc questionnaire in order to collect
data on hospital resources consumption. RESULTS: A total of
201 patients were enrolled in the study (mean age: 66.2 „b 15.4),
of which 48.8% was male. Most of the patients (80.4%) were
admitted the ER in the ﬁrst 48 hours after the AT event. Out of
the 201 patients (44.3%) declared that was their ﬁrst AT episode.
At the moment of the event 46.7% of the patients were not
assuming any pharmacological therapy, 21.9% were assuming
anti-aggregate, 7.5% anticoagulant, 39.8% anti-arrhythmic
drugs and 5% were already implanted with a Pacemaker. A total
of 818 diagnostic test and therapeutic procedures were per-
formed, which means, on average, 4.1 per patient. The most 
performed were ECG followed by blood test, pharmacological
cardioversion, chest X-ray, in-hospital ECG monitoring, 24-hour
holter monitoring, and external cardioversion. Out of the total
patients, 148 were discharged from the ER, 31 patients were hos-
pitalized in the “department of short-term observation” (average
length of staying (LOS): 1.3 days), 8 patients were hospitalized
in the cardiological department (average LOS: 7 days), 12 were
hospitalized in other departments (average LOS: 4 days) and
only 2 patients had different destination. CONCLUSIONS: This
study shows that ATs, even if they are not life-threatening dis-
eases and most patients are discharged directly from ER, absorb
a relevant amount of hospital resources. Future economic eval-
uation of this data will highlight also the impact of ATs on the
hospital and NHS expenses.
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OBJECTIVES: To establish the current level of resource utilisa-
tion required to monitor International Normalised Ratio (INR)
levels in patients treated with warfarin in the UK National
Health Service. METHODS: Monitoring services in areas asso-
ciated with six secondary care Trusts were studied. Accurate
descriptions of services were obtained through one-to-one semi-
structured interviews with NHS staff involved in the delivery of
anticoagulant monitoring. Due to the complexity of the differ-
ent systems, where possible, resource use was divided into the 3
main steps: taking blood (including transport of patients and/or
bloods), INR analysis, and the communication of results and
warfarin dose changes. Costs associated with running the service
were identiﬁed and sourced from local settings or NHS reference
costs as appropriate (2004 prices). RESULTS: The six monitor-
ing services were responsible for an average of 3459 (Range
1422–4500) warfarin patients, with a mean frequency of INR
monitoring of 14.2 times per year (SD 3.4). The average cost of
a monitoring visit was £14.58 (SD 4.25), of which £6.88 as asso-
ciated with taking bloods, £4.08 with analysis and £3.62 with
communication of results and dose changes. The mean annual
cost per patient of INR monitoring was £206.41 (SD 63.51).
Three of the services had separate hospital and primary/shared
care models of INR monitoring. In these services the cost per
INR test tended to be lower in the hospital based model (Mean
£13.39) than in models that included primary care (Mean
£23.06). CONCLUSIONS: The cost of INR monitoring varies
according to setting and system. Where monitoring involves
primary care, it tends to be more costly than systems in which
hospital anticoagulation clinics control monitoring and warfarin
treatment. This may be due to economies of scale and the ability
of specialist clinics to deal with the monitoring process more 
efﬁciently.
